Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

A Study to Provide Access to Trabectedin in Participants With Locally Advanced or Metastatic Soft Tissue Sarcoma Who Have Persistent or Recurrent Disease and Who Are Not Expected to Benefit From Currently Available Standard of Care Treatment

Expanded access is no longer available for this treatment.
Information provided by (Responsible Party):
Janssen Research & Development, LLC Identifier:
First received: September 13, 2005
Last updated: October 7, 2016
Last verified: October 2016